Canada Women’s Health Market Size & Outlook, 2023-2030
Canada women’s health market, 2018-2030 (US$M)
Related Markets
Canada women’s health market highlights
- The Canada women’s health market generated a revenue of USD 1,612.5 million in 2023 and is expected to reach USD 2,530.5 million by 2030.
- The Canada market is expected to grow at a CAGR of 6.6% from 2024 to 2030.
- In terms of segment, postmenopausal osteoporosis was the largest revenue generating application in 2023.
- Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
Women’s health market data book summary
| Market revenue in 2023 | USD 1,612.5 million |
| Market revenue in 2030 | USD 2,530.5 million |
| Growth rate | 6.6% (CAGR from 2023 to 2030) |
| Largest segment | Postmenopausal osteoporosis |
| Fastest growing segment | Endometriosis & Uterine Fibroids |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, Canada accounted for 3.6% of the global women’s health market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. women’s health market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 2,530.5 million by 2030.
Postmenopausal osteoporosis was the largest segment with a revenue share of 30.07% in 2023. Horizon Databook has segmented the Canada women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.
The growing prevalence of PCOS, menopause, & infertility and the increase in usage of contraceptives as well as the subsequent rise in the rate of treatment in Canada are some of the key factors anticipated to boost the demand for women’s health products.
In addition, according to a report published by Canada’s government, around one in six couples experiences infertility in Canada. Some of the major causes of women’s infertility are hormonal imbalance and endometriosis. All these factors are expected to propel the demand for women’s health products in Canada.
Rising healthcare expenditure on women’s health is expected to drive market growth. For instance, in April 2021, the Canadian federal government planned to spend nearly USD 45 million over 3 years to make reproductive and sexual health services & information accessible.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Women’s Health Market Scope
Women’s Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Canada women’s health market size, by application, 2018-2030 (US$M)
Canada Women’s Health Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
